Spur Therapeutics has announced that its gene therapy candidate for Gaucher disease will soon be moving to a Phase III trial ...
Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...